Core Viewpoint - The report from China Merchants Securities (Hong Kong) maintains a "Buy" rating for CSPC Pharmaceutical Group (1093.HK) with a target price of HKD 13.93, highlighting the company's strategic partnership with AstraZeneca valued at USD 1.85 billion, which validates the value of its AI-driven and long-acting peptide platform [1] Group 1: Financial Performance - The company has seen continuous realization of BD (Business Development) revenue, indicating strong financial performance [1] - For the first nine months of 2025, the core business has shown a quarter-on-quarter improvement, with a decrease in the sales expense ratio [1] - The DCF (Discounted Cash Flow) valuation has been adjusted upwards, reflecting enhanced visibility of earnings driven by BD [1] Group 2: Strategic Developments - The partnership with AstraZeneca is a significant milestone, emphasizing the potential of the company's innovative platforms [1] - The focus on high-intensity R&D investment remains a priority for the company, supporting its long-term growth strategy [1]